Speciality Medicines IPO Analysis

Speciality Medicines Limited (Feb 2021) is planning a BSE SME IPO with 23.5 lakh fresh shares (100% primary issue), implying 26.75% dilution, with a market maker portion of 1.5 lakh shares and a floor price of ₹117. The company is engaged in the business of speciality pharma distribution with a focus on high-value segments like oncology and critical care, wherein margins are better due to premium pricing models. The business is working capital-intensive, with inventory holdings of expensive drugs and hospital credit, so growth is dependent on capital raised through this IPO.

The Opportunity and The Risks

Promoters

The company is promoted by Parth Goyani and Sumit Goyani, both of whom are associated with the company since its incorporation in 2021. The company was initially incorporated as a private limited company, which was later converted to a public limited company in June 2024.

Parth Goyani is the Chairman and Managing Director of the company. He is responsible for managing the overall business strategy, supplier relationships, as well as building the distribution network. Parth plays a significant role in growing the business in terms of size in the speciality pharma segment.

Sumit Goyani is a Whole-Time Director. He is responsible for the execution of the business strategy, supply chain management, as well as relationships with institutional clients. Both the promoters play a significant role in growing the business in a relationship-driven, working capital-intensive business.

Speciality Medicines Limited follows a working capital-intensive distribution strategy, which is very different from the asset-light business model of the company. Though the company does not need significant capital expenditure in terms of machinery and equipment, the business still needs high capital expenditure in terms of inventory and debtors to achieve high growth.

The company reported revenue of ₹58.27 Cr in FY25 with the help of its distribution strategy and relationships with its suppliers. However, unlike technology-based businesses, the business grows with the expansion of the balance sheet as well.

Inventory: ₹17.37 Cr (30% of revenue)

Receivables: ₹9.58 Cr (16% of revenue)

Inventory + Receivables: ₹26.95 Cr (46% of revenue)

Fixed Assets: ₹1.86 Cr (3% of total assets)

This indicates that the business is asset-light in terms of fixed assets but is highly capital-intensive in terms of working capital.

Working Capital-Driven Distribution Model

The business model is based on the distribution of high-value pharmaceutical products.

The major factors that can add to the growth of the distribution business are:

• Increase in the client base of hospitals and institutions.

• Increase in the portfolio of products.

• Increase in the deployment of inventory.

• Increase in the efficiency of inventory turnover.

This is very different from the platform business model, where the business grows with the increase in the balance sheet.

The business grows with the expansion of the balance sheet as the revenue grows with the expansion of the balance sheet.

Balance Sheet & Leverage Profile

Generally, distribution businesses operate with moderate leverage, especially during periods of rapid growth.

• Total Assets: ₹37.57 Cr

• Net Worth: ₹30.42 Cr

• Borrowings: ~₹5.04 Cr

• Working Capital (Inventory + Receivables): ~₹27 Cr (~72% of assets)

The capital structure reflects the working capital-based growth model, which is dependent on internal accruals as well as external borrowings.

The balance sheet is highly skewed towards current assets, which implies:

• High dependence on liquidity

• Sensitivity to credit cycle

• Risk of capital lock-in

For the speciality pharma distribution business, the cash flows are driven by:

• Inventory procurement

• Credit furnished to hospitals/institutions

• Supplier payment terms

The company has reported:

Operating Cash Flow (FY25): -₹5.79 Cr

Negative CFO in FY24 as well

This implies that despite the company’s profitability, the cash is going into the expansion of working capital.
The cash flow volatility is a major risk, as the business needs to reinvest its cash continuously, and the company’s profitability does not immediately convert into cash.

Profitability Matrix

The company has demonstrated robust profitability growth along with scale-up:

Revenue: ₹27.65 Cr (FY24) → ₹58.27 Cr (FY25)

Profit After Tax: ₹2.93 Cr → ₹8.60 Cr

Profit After Tax Margin: ~14.7% (FY25)

While the company’s margins may seem robust for a distribution business, the sustainability of the same is a major concern.

While the current margins may benefit from the early-stage scale advantages as well as the procurement spreads, the margins of the company may normalize over time, as is the case with most distribution businesses.

Structural View

The company has a hybrid business model, with an asset-light business as well as a capital-intensive working capital model.

Fixed assets are minimal: ~₹1.86 Cr

The company is growing its inventory as well as receivables: ~₹27 Cr base

Core Insight: Unlike platform businesses, however, scalability is not without limits, as it is impacted by:

• Working capital availability

• Credit discipline

• Supplier relationships

Peer Comparison

Peer Comparison Table

The revenue from operations has shown an increase from ₹23.17 Cr in FY23 to ₹58.27 Cr in FY25, with a robust 2-year CAGR of ~58%, signifying rapid scale-up in a short operating history. The company has shown a sharp rise in profitability, with PAT increasing from ₹1.70 Cr in FY23 to ₹8.61 Cr in FY25, ~5 times growth, along with robust ROE of 37.85% in FY25.

The company has a working capital-driven distribution model, which is asset-light in the form of fixed assets of ₹1.86 Cr, but capital-intensive with inventory of ₹17.37 Cr and receivables of ₹9.58 Cr, leading to high asset turnover of 1.55x, though with poor cash flow conversion, with CFO turning negative in FY23, FY24, and FY25.

LMVT Framework

The company operates in the speciality pharma distribution space, serving hospitals and healthcare institutions with high-end therapies like oncology and critical care.

The company has shown robust growth in the past, driven by increasing demand for speciality drugs, expansion of the hospital network, and the rise of chronic therapies.

The company is now looking at the public markets, and going ahead, the company’s growth is dependent on:

• Expansion of the client base of hospitals/clinics

• Scaling the working capital base

• Enhancing the relationship with the suppliers

Moat

The entry barriers for the company in the Pharma Distribution space are moderate, with limited scope of differentiation beyond relationships and efficiency.

The company’s competitive advantage is:

• Supplier relationships with Pharma Companies

• Institutional relationships with hospitals

• Ability to manage high-value inventory and distribution

However, unlike pharma manufacturers, the business doesn’t have a product/IP moat; hence, it is an execution-driven model.

Valuation

The company is seeking a market capitalisation of ~ ₹108-110 Cr at the upper price band of ₹124. Based on FY25 earnings:

• P/E = ~8.8x

• EV/EBITDA = ~10-12x (approx.)

Compared with peers:

Remus Pharmaceuticals - 25x P/E

Trident Lifeline - 18x P/E

The company is trading at a discount, which is justified:

• Small scale

• Working capital intensive model

• Poor cash flow generation

Tailwinds

The speciality pharma industry in India is growing at 12-15% CAGR on account of:

• Increasing incidence of cancer and chronic diseases

• Improving access and infrastructure in the healthcare and hospital industry

• Adoption of expensive treatment options

Thus, there is a huge demand for distributors of speciality medicines.

Conclusion

Speciality Medicines is a high-growth, early-stage pharma distributor with ~58% revenue CAGR, high profitability growth, and high ROE of ~38%. However, the business is working capital intensive with negative operating cash flows and high dependency on inventory and credit management.

The company is trading at attractive valuations with a P/E of ~8.8x. However, the business quality is low compared with pharma manufacturer peers on account of the absence of a moat and poor cash flow generation.Investors must note that this is a growth-driven business with dependency on cash flows and is better suited for listing gains.